6533b862fe1ef96bd12c6cb5
RESEARCH PRODUCT
An Organometallic Gold(I) Bis‐N‐Heterocyclic Carbene Complex with Multimodal Activity in Ovarian Cancer Cells
Klaus G. SchmettererGunda KoellenspergerMargit Cichna-marklMartin SchaierChristopher GernerChristopher GernerGiorgia Del FaveroAngela CasiniBenjamin NeuditschkoKatja ZappeRiccardo BonsignoreSamuel M. Meier-menchesMarlene C. Gernersubject
ProteomicsNucleolusCancer | Very Important PaperContext (language use)Antineoplastic Agents010402 general chemistryProteomicsG-quadruplex01 natural sciencesCatalysischemistry.chemical_compoundgold complexesCaffeineCell Line TumorOrganometallic CompoundscancerHumansN-heterocyclic carbenesShotgun proteomicsMode of actionOvarian NeoplasmsFull Paper010405 organic chemistryChemistryOrganic ChemistryGeneral ChemistryFull PaperstelomeresG-quadruplexes0104 chemical sciencesddc:BiochemistryCancer cellFemaleGoldCarbeneMethanedescription
Abstract The organometallic AuI bis‐N‐heterocyclic carbene complex [Au(9‐methylcaffeine‐8‐ylidene)2]+ (AuTMX2) was previously shown to selectively and potently stabilise telomeric DNA G‐quadruplex (G4) structures. This study sheds light on the molecular reactivity and mode of action of AuTMX2 in the cellular context using mass spectrometry‐based methods, including shotgun proteomics in A2780 ovarian cancer cells. In contrast to other metal‐based anticancer agents, this organogold compound is less prone to form coordinative bonds with biological nucleophiles and is expected to exert its drug effects mainly by non‐covalent interactions. Global protein expression changes of treated cancer cells revealed a multimodal mode of action of AuTMX2 by alterations in the nucleolus, telomeres, actin stress‐fibres and stress‐responses, which were further supported by pharmacological assays, fluorescence microscopy and cellular accumulation experiments. Proteomic data are available via ProteomeXchange with identifier PXD020560.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-11-03 |